MAP2K7 and pancreatic neoplasm: Based on the MEK signaling pathway, which is the major driver of tumor formation, and being a promising therapeutic approach in pancreatic cancer, Szlachta et al. validated genes whose depletion synergistically augments cellular sensitivity to MEK inhibition through large-scale in vivo and in vitro CRISPR knockout screens in pancreatic cancer cells.